CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Condition: Solid Tumor or Lymphoma
Sponsor: CStone Pharmaceuticals
Full Title
Protocol CS5001 -101: A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Eligibility
Patients must have progressed on or been intolerant to available standard therapies that are known to provide clinical benefit
- Solid Tumor: progression on/after at least 1 prior line of therapy in the advanced/metastatic setting
- Non-Hodgkin B-Cell Lymphoma: progression on/after at least 2 prior lines of therapy
- Hodgkin Lymphoma: relapsed/refractory after prior treatment with brentuximab vedotin and at least one checkpoint inhibitor
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
